{"nctId":"NCT00655486","briefTitle":"Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures","startDateStruct":{"date":"2008-04"},"conditions":["Partial Epilepsies","Partial Onset Seizures"],"count":97,"armGroups":[{"label":"Lacosamide","type":"EXPERIMENTAL","interventionNames":["Drug: lacosamide"]}],"interventions":[{"name":"lacosamide","otherNames":["Vimpat"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eligible subjects who participated in SP925 \\[NCT00655551\\] for treatment of partial-onset seizures\n\nExclusion Criteria:\n\n* Receiving any study drug or experimental device other than lacosamide\n* Meets withdrawal criteria for parent study SP925 \\[NCT00655551\\]\n* Experiencing ongoing serious adverse event","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study (Maximum Study Duration 2 Years)","description":"An Adverse Event (AE) is any untoward medical occurrence (eg, noxious or pathological changes) in a subject or clinical investigation subject compared with pre-existing conditions, that occurs during any period of a clinical trial including Pre-treatment, Run-In, Wash-Out, or Follow-Up Periods. An AE is defined as being independent of assumption of any causality (eg, to study or concomitant medication, primary or concomitant disease, or study design).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Withdrew From the Study Due to an Adverse Event (Maximum Study Duration 2 Years)","description":"An Adverse Event (AE) is any untoward medical occurrence (eg, noxious or pathological changes) in a subject or clinical investigation subject compared with pre-existing conditions, that occurs during any period of a clinical trial including Pre-treatment, Run-In, Wash-Out, or Follow-Up Periods. An AE is defined as being independent of assumption of any causality (eg, to study or concomitant medication, primary or concomitant disease, or study design).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":97},"commonTop":["Dizziness","Diplopia","Vomiting","Upper respiratory tract infection","Nausea"]}}}